♦ About Gongwin BioPharm Holdings, Co., Ltd. ♦
Gongwin Biopharm Holdings, Co., Ltd. Cayman (Gongwin-KY; ticker: 6617) founded in 2014 is a Taiwan-based clinical-stage biopharmaceutical company focused on developing novel anti-cancer drugs. We adopt an innovative anti-tumor therapy called “minimally-invasive targeted tumor ablation” (MITTA) therapy for the treatment of focal malignancies. In 2017, Gongwin-KY has been granted “Biotech New Drug Company” designation by MOEA, Taiwan and became a public trading company at Taipei Emerging Stock Board.
The proprietary core technology of Gongwin-KY is intratumoral injection of PTS (para-toluenesulfonamide) by combining the active therapeutic agent-PTS and minimally-invasive intervention, which is unique and distinct from traditional anti-tumor therapies. The advantages include targeting specific tumors plus the nature of high selectivity of PTS on tumor cells. Based on a completed Phase III clinical trial conducted in China, PTS MITTA therapy has demonstrated its safety showing minimal damages to adjacent normal cells and efficacy by statistical analysis. Gongwin-KY is confident to provide PTS MITTA as a better novel anti-cancer treatment option.
Following are Gongwin-KY’s new drug candidates under development.
- PTS302 (for the treatment of lung cancer)：
- In 2018, PTS302 was inspected, registered, and classified by CFDA as Class1 new drug, under special & priority review for approval.
- In 2019, the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China has completed the clinical evaluation of PTS302. The pharmacy materials, indications and instructions for use, and post-launch risk control plans are under review.
- In 2022, the new drug approval of PTS302 in China was officially issued in November.
- Phase II clinical trial of liver cancer has been carried out at National Taiwan University Hospital, Taipei Veterans General Hospital, and Taipei University Hospital.
3. PTS-02 (for the treatment of Adenoid cystic carcinoma (ACC)：
The orphan drug designation from the U.S. Food and Drug Administration (FDA) was obtained in 2019, and the Phase II clinical trial application to the U.S. FDA for will be submitted in the near future.
4. PTS500 (for the treatment of Malignant pleural effusion)：
- The clinical trial application is expected to be submitted in Taiwan, China, Australia, etc.
Dr. Wu, the inventor of PTS, and Dr. Shih have been conducting various exploratory studies on PTS since 1980s. In 2000, PTS International Inc., Texas, USA, and Beijing Vision Drugs Development Limited were established in China to conduct multiple pre-clinical studies and clinical trials. Since then, we have accumulated a great deal of clinical data and experience on PTS anti-cancer therapy. In 2011, a Phase III multi-center, non-randomized, single-arm, open-label trial has been completed in China. Afterward, a category 1.1 NDA has been submitted to China FDA. In order to accommodate the local regulatory affairs and markets in China, Tianjin Chase Sun Jiandakang Pharmaceutical Technology Co., Ltd. was founded by PTS International Inc. and Tianjin Chase Sun Pharmaceutical Co., Ltd. to be responsible for the license registration and manufacturing of PTS for China market.
Gongwin-KY focus on the development of PTS MITTA anti-cancer novel drugs and other new drugs for unmet medical needs. Our ultimate goal is to provide effective and safe novel drug with high quality. Gongwin-KY’s corporate culture is based on four core values:
Providing a novel loco-regional tumor ablation therapy based on Gongwin-KY’s MITTA core competency,
Maximizing corporate value and company competitiveness under the leadership of seasoned management team
Bracing the golden rule of being honest and truthful and creating a triple-win situation among patients, physicians and investors
Fulfilling corporate social responsibility and caring for life. After cured by PTS MITTA, patients can extend his or her happiness to family and friends.